Sanofi Consumer Healthcare India Limited (SANOFICONR) Q4 2025 earnings summary

Executive summary

• Audited standalone financial statements for the year ended December 31, 2025, were approved, with an unmodified audit opinion issued by the statutory auditors.

• A final dividend of ₹75 per equity share was recommended for FY25, pending shareholder approval at the AGM.

• Re-appointment of M/s. Kishore Bhatia & Associates as Cost Auditor for FY26 was approved.

Financial highlights

• Revenue from operations for FY25 was ₹8,045 million, up from ₹6,689 million in FY24.

• Net profit for FY25 stood at ₹2,401 million, compared to ₹1,810 million in FY24.

• Q4 FY25 revenue was ₹2,330 million, with net profit at ₹665 million.

• Domestic sales grew 7% and export sales surged 158% year-over-year for FY25.

• Exceptional items in FY25 included a reversal of ₹66 million related to demerger provisions.

Outlook and guidance

• The company relaunched key products (Depura Adult, Combiflam Suspension, Allegra Suspension, Depura Kids) during FY25, impacting comparability with the previous year.

• The company will continue to monitor the impact of new Labour Codes and adjust employee benefit obligations as needed.